Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia

Psychiatry Research

Volumn 187, Issue 1-2, 2011, Pages 49-54

  Andersen, Rune ^a,b   Fagerlund, Birgitte ^a   Rasmussen, Hans ^a   Ebdrup, Bjorn H ^a   Aggernaes, Bodil ^a   Gade, Anders ^b   Oranje, Bob ^a   Glenthoj, Birte ^a  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antipsychotic na ve; Cognition; First episode; Quetiapine; Schizophrenia

Indexed keywords

QUETIAPINE;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE; WORKING MEMORY;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; COGNITION DISORDERS; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 79953081209     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.10.013     Document Type: Article

References (63)

1. Baddeley A., Emslie H., Nimmo-Smith I., Edmunds B. SCOLP - The Speed and Capacity of Language-Processing Test 1992, Thames Valley Test Company, Suffolk.
2. Bilder R.M., Goldman R.S., Robinson D., Reiter G., Bell L., Bates J.A., Pappadopulos E., Willson D.F., Alvir J.M., Woerner M.G., Geisler S., Kane J.M., Lieberman J.A. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. The American Journal of Psychiatry 2000, 157:549-559.
3. Blyler C.R., Gold J.M. Cognitive effects of typical antipsychotic treatment: another look in cognitive deficits in schizophrenia. Cognition in Schizophrenia: Impairment, Importance and Treatment Strategies 2000, 241-265. Oxford University Press, Oxford. T. Sharma, P.D. Harvey (Eds.).
4. Buschke H. Selective reminding for analysis of memory and learning. Journal of Verbal Learning and Verbal Behavior 1973, 125:543-550.
5. Carpenter W.T., Gold J.M. Another view of therapy for cognition in schizophrenia. Biological Psychiatry 2002, 51:969-971.
6. Crespo-Facorro B., Rodríguez-Sánchez J.M., Pérez-Iglesias R., Mata I., Ayesa R., Ramirez-Bonilla M., Martínez-Garcia O., Vázquez-Barquero J.L. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. The Journal of Clinical Psychiatry 2009, 705:717-729.
7. Davidson M., Galderisi S., Weiser M., Werbeloff N., Fleischhacker W.W., Keefe R.S., Boter H., Keet I.P., Prelipceanu D., Rybakowski J.K., Libiger J., Hummer M., Dollfus S., López-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rössler A., Kahn R.S. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial EUFEST. The American Journal of Psychiatry 2009, 1666:675-682.
8. Fagerlund B., Mackeprang T., Gade A., Glenthøj B.Y. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectrums 2004, 95:364-374.
9. Fioravanti M., Carlone O., Vitale B., Cinti M.E., Clare L. A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychology Review 2005, 152:73-95.
10. Gold J.M., Rehkemper G., Binks S.W., Carpenter C., Fleming K., Goldberg T.E., Weinberger D.R. Learning and forgetting in schizophrenia. Journal of Abnormal Psychology 2000, 1093:534-538.
11. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.S., Woerner M.G., Schooler N.R., Kane J.M., Robinson D.G. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia. Is it a practice effect?. Archives of General Psychiatry 2007, 6410:1115-1122.
12. Good K.P., Kiss I., Buiteman C., Woodley H., Rui Q., Whitehorn D., Kopala L. Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. The British Journal of Psychiatry 2002, 43:45-49.
13. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. The American Journal of Psychiatry 1996, 153:321-330.
14. Green M.F., Braff D.L. Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biological Psychiatry 2001, 49:374-384.
15. Green M.F., Nuechterlein K.H. Should schizophrenia be treated as a neurocognitive disorder?. Schizophrenia Bulletin 1999, 25:309-319.
16. Harvey P.D., Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. The American Journal of Psychiatry 2001, 1582:176-184.
17. Heres S., Davis J., Maino K., Jetzinger E., Kissling W., Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. The American Journal of Psychiatry 2006, 163:185-194.
18. Hill S.K., Sweeney J.A., Hamer R.M., Keefe R.S., Perkins D.O., Gu H., McEvoy J.P., Lieberman J.A. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. Journal of the International Neuropsychological Society 2008, 142:209-221.
19. Hill S.K., Bishop J.R., Palumbo D., Sweeeney J.A. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Review of Neurotherapeutics 2010, 10:43-57.
20. Kapur S., Zipursky R., Jones C., Shammi C.S., Remington G., Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Archives of General Psychiatry 2000, 57:553-559.
21. Kay S.R. Positive and Negative Syndromes in Schizophrenia 1991, Brunner/Mazel, New York.
22. Keefe R.S., Silva S.G., Perkins D.O., Lieberman J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bulletin 1999, 252:201-222.
23. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry 2007, 646:633-647.
24. Keefe R.S., Sweeney J.A., Gu H., Hamer R.M., Perkins D.O., McEvoy J.P., Lieberman J.A. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. The American Journal of Psychiatry 2007, 1647:1061-1071.
25. Keefe R.S., Malhotra A.K., Meltzer H.Y., Kane J.M., Buchanan R.W., Murthy A., Sovel M., Li C., Goldman R. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2008, 33:1217-1228.
26. Keshavan M.S., Rosenberg D., Sweeney J.A., Pettegrew J.W. Decreased caudate volume in neuroleptic-naive psychotic patients. The American Journal of Psychiatry 1998, 1556:774-778.
27. Kravariti E., Morgan K., Fearon P., Zanelli J.W., Lappin J.M., Dazzan P., Morgan C., Doody G.A., Harrison G., Jones P.B., Murray R.M., Reichenberg A. Neuropsychological functioning in first-episode schizophrenia. The British Journal of Psychiatry 2009, 195:336-345.
28. Levaux M.N., Potvin S., Sepehry A.A., Sablier J., Mendrek A., Stip E. Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. European Psychiatry 2007, 22:104-115.
29. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine 2005, 353:1209-1223.
30. Lowe C., Rabbitt P. Test/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues. Cambridge Neuropsychological Test Automated Battery. International Study of Post-Operative Cognitive Dysfunction. Neuropsychologia 1998, 36:915-923.
31. McEvoy J.P., Hogarty G.E., Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry 1991, 488:739-745.
32. Meltzer H.Y., Thompson P.A., Lee M.A., Ranjan R. Neuropsychological deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology 1996, 14:27-33.
33. Mesholam-Gately R.I., Giuliano A.J., Goff K.P., Faraone S.V., Seidman L.J. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009, 233:315-336.
34. Meyers J., Meyers K. Rey Complex Figure and Recognition Trial: Professional Manual 1995, Psychological Assessment Resources, Florida.
35. Milner B. Effects of different brain lesions on card sorting. Archives of Neurology 1963, 19:90-100.
36. Milner B. Psychological aspects of focal epilepsy and its neurological management. INSERM Symposium 1975, 6. Elsevier/North Holland, Amsterdam. D.P. Rougeul-Buser (Ed.).
37. Mishara A.L., Goldberg T.E. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biological Psychiatry 2004, 55:1013-1022.
38. Nasrallah H.A., Tandon R. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. The Journal of Clinical Psychiatry 2002, 6313:12-20.
39. Nelson H.E. National Adult Reading Test NART: Test Manual 1982, NFER-Nelson, Windsor.
40. Perkins D.O., Gu H., Weiden P.J., McEvoy J.P., Hamer R.M., Lieberman J.A. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. The Journal of Clinical Psychiatry 2008, 691:106-113.
41. Purdon S.E., Malla A., Labella A., Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. Journal of Psychiatry & Neuroscience 2001, 26:137-149.
42. Regard M., Strauss E., Knapp P. Children's production of verbal and nonverbal fluency tasks. Perceptual and Motor Skills 1982, 55:839-844.
43. Reitan R.M., Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation 1993, Neuropsychology Press, Tucson, AZ.
44. Riedel M., Müller N., Strassnig M., Spellmann I., Severus E., Möller H.J. Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatric Disease Treatment 2007, 32:219-235.
45. Sahakian B.J., Owen A.M. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. Journal of the Royal Society of Medicine 1992, 85:399-402.
46. Salimi K., Jarskog L.F., Lieberman J.A. Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs 2009, 2310:837-855.
47. Sax K.W., Strakowski S.M., Keck P.E. Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophrenia Research 1998, 33:151-155.
48. Schedules for clinical assessment in neuropsychiatry 1994, World Health Organization.
49. Seeman P., Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to D2 receptors yet occupy high levels of these receptors. Molecular Psychiatry 1998, 3:123-134.
50. Szöke A., Trandafir A., Dupont M.E., Méary A., Schürhoff F., Leboyer M. Longitudinal studies of cognition in schizophrenia: meta-analysis. The British Journal of Psychiatry 2008, 1924:248-257.
51. Tandon R. Quetiapine has a direct effect on the negative symptoms of schizophrenia. Human Psychopharmacology 2004, 19:559-563.
52. Velligan D.I., Miller A.L. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. The Journal of Clinical Psychiatry 1999, 6023:25-28.
53. Velligan D.I., Kern R.S., Gold J.M. Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. Schizophrenia Bulletin 2006, 323:474-485.
54. Voruganti L.P., Cortese L., Ouyewumi L., Cernovsky J., Zirul S., Awad A. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophrenia Research 2002, 57:201-208.
55. Voruganti L.P., Awad A.G., Parker G., Forrest C., Usmani Y., Fernando M.L., Senthilal S. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research 2007, 961-3:146-155.
56. Wechsler D. Manual for the Wechsler Adult Intelligence Scale WAIS 1955, The Psychological Corporation, San Antonio, Texas.
57. Wechsler D. The Wechsler Adult Intelligence Scale-Revised 1981, The Psychological Corporation, San Antonio, Texas.
58. Weickert T.W., Goldberg T.E. First- and second-generation antipsychotic medication and cognitive processing in schizophrenia. Current Psychiatry Reports 2005, 7:304-310.
59. Weickert T.W., Terrazas A., Bigelow L.B., Malley J.D., Hyde T., Egan M.F., Weinberger D.R., Goldberg T.E. Habit and skill learning in schizophrenia: evidence of normal striatal processing with abnormal cortical input. Learning & Memory 2002, 96:430-442.
60. Wittorf A., Sickinger S., Wiedemann G., Klingberg S. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study. Archives of Clinical Neuropsychology 2008, 23:271-282.
61. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. The International Journal of Neuropsychopharmacology 2005, 8:1-16.
62. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophrenia Research 2007, 891-3:211-224.
63. Zhong K.X., Sweitzer D.E., Hamer R.M., Lieberman J.A. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. The Journal of Clinical Psychiatry 2006, 677:1093-1103.